Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025KT-621 Phase 1b trial in atopic dermatitis ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

Get a detailed analysis of the latest innovations in the IgG4-Related Disease pipeline. Explore DelveInsight's expert-driven report today! @ IgG4-Related Disease Unmet Needs Amgen, Sanofi ...

Credit: Shutterstock / Saiful52. Johnson and Johnson (J&J) has announced the cancellation of its Phase III E.mbrace study examining Sanofi’s investigational vaccine for extraintestinal pathogenic ...

The company’s NBD1 research was licensed from Sanofi. Last July, Sionna expanded its pipeline by licensing three clinical-stage CF drugs that AbbVie developed under a partnership with Galapagos.